| Objective:To study atorvastatin calcium (Ale) on the non-ischemic heart failure or dilated cardiomyopathy (HF; DCM) patients with left ventricular ejection fraction (LVEF), New York Heart Association (NYHA) cardiac function, blood C-reactive protein (CRP), flow-mediated endothelium-dependent vasodilation (FMD), plasma total cholesterol (TC), low density lipoprotien (LDL) influence, for the treatment of DCM Ale to provide more clinical basis. Methods:60 patients with DCM were selected, all from the Department of Cardiology, Hospital of Luzhou City, from June 2008 to February 2010 DCM HF hospitalization in patients aged 42-83 years old, were randomly divided into Ale group and control group 30 cases of which Ale group were 18 males and 12 females, aged (51.2±9.1) years of age, heart failure time (4.1±1.3), the control group including 19 males and 11 females, aged (53.1±8.4) years of age, heart failure time (3.8±1.1) years. Two groups in age, gender, disease duration, blood pressure, heart rate and other aspects of the general situation was no significant difference (P>0.05). As the case patients were given conventionally basic therapy (digitalis, ACEI, (3 blockers, diuretics); Ale group were added Ale 10mg/d in the treatment for 12 months, respectively. Before treatment,3-month treatment and 12-month treatment,the two groups were tested NYHA classification,LVEF,CRP,FMD,TC,LDL.The indicators were the single factor analysis of variance,t test,the Chi-square test and the Pearson correlation analysis.Results:The patients in age,gender,disease duration, blood pressure,heart rate and the basic treatment routine were no significant difference(P>0.05).1.In the treatment of 3 months and 12 months Atorvastatin group and control group,the CRP,TC,and LDL decreased,but the EF,NYHA classification,and the average increased in FMD in the water.but the Atorvastatin group in the CRP,TC and lower LDL levels and in EF,NYHA classification,and the increase in FMD levels were higher than the control group(P<0.05),after treated for 3 months.Atorvastatin group and control group:CRP(3.52±1.12 mg/L VS 5.26±1.92mg/L),EF(37.92±6.09% VS 34.96±4.96%),NYHA classification(2.26±0.82 VS 2.70±0.83),FMD(5.15±0.86% VS 4.60±0.58%),TC(3.13±0.48 mmol/L VS 3.43±0.58mmol/L),LDL(2.85±0.59 mmol/L VS 3.24±0.33mmol/L),P<0.05；treatment for 12 months Atorvastatin group and control group:CRP(2.02±1.33 mg/L VS 4.51±1.26mg/L),EF(49.33±8.50% VS 36.26±5.90%),NYHA classification (1.90±0.0.75 VS 2.33±0.88),FMD(7.01±1.50% VS 4.62±0.64%),TC (2.85±0.47mmol/L VS 3.34±0.45mmol/L),LDL(2.25±0.41mmol/ L VS 3.20±0.50mmol/L),P<0.05.2.In the Atorvastatin group EF and CRP levels were significantly negatively correlated(r=-0.517,P<0.01), EF and FMD levels were significantly correlated(r=0.707,P<0.01),while EF and TC, LDL were not correlation; control group, EF and CRP, FMD, TC, LDL levels were not correlation.Conclusion:1. DCM heart failure patients based on conventional therapy plus atorvastatin 10mg/d treated for 3 months and 12 months of treatment could significantly improve left ventricular function and endothelial function,and reduced blood CRP, TC, LDL levels.2. Atorvastatin could improve cardiac function in patients with DCM by reduced the CRP,and improved endothelial function to achieve, independent of lipid-lowering beyond. |
PDF Full Text Request